GlassScriptPhysician profile
Cesar D Rios
NPI 1124075064
$5,368.98
in general payments reported to CMS, 2019-2025
34 companies · $531 in 2025
The $531 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $625 · 2020: $436 · 2021: $1,139 · 2022: $756 · 2023: $783 · 2024: $1,099 · 2025: $531.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,414.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,413.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $506.97 | 2019-2025 | Repatha, Repatha |
| Pfizer INC. | $395.06 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $369.47 | 2019-2025 | |
| Impulse Dynamics (USA) INC. | $361.87 | 2021-2023 | Optimizer |
| E.R. Squibb & Sons, L.L.C. | $349.89 | 2019-2025 | Camzyos, Eliquis |
| Biotronik INC. | $328.42 | 2019-2021 | |
| Abiomed | $312.34 | 2019-2022 | |
| Novo Nordisk INC | $239.71 | 2023-2025 | Wegovy, Ozempic |
| Merck Sharp & Dohme LLC | $235.31 | 2021-2025 | Verquvo |
| Abbott Laboratories | $216.67 | 2021 | |
| Janssen Pharmaceuticals, INC | $208.33 | 2019-2024 | Xarelto |
| Lantheus Medical Imaging, INC. | $207.29 | 2021-2025 | Definity |
| Medtronic, INC. | $191.66 | 2021-2025 | Cobalt Dr Mri Surescan, Hawkone, Onyx Frontier |
| Scpharmaceuticals INC. | $174.41 | 2023-2024 | |
| Boston Scientific Corporation | $128.54 | 2019-2025 | Watchman Flx |
Show all 34 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cesar Rios listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.